Claire Mazumdar named successor to Biocon founder Kiran Mazumdar-Shaw

Key facts

• Biocon founder and chairperson Kiran Mazumdar-Shaw named her 37-year-old niece Claire Mazumdar as her successor for the biotechnology company.
• Claire Mazumdar is the founder and Chief Executive Officer (CEO) of Bicara Therapeutics, a National Association of Securities Dealers Automated Quotations (NASDAQ) listed firm with a market capitalisation of over $1.6 billion.
• Claire Mazumdar holds degrees from Massachusetts Institute of Technology (MIT) and Stanford University, including a PhD in cancer biology.
• Shreehas Tambe has taken over as the CEO and Managing Director (MD) of Biocon Biologics, while Siddharth Mittal is set to lead Syngene International from 1 July.
• Biocon has merged its generics and biologics businesses, with biosimilars currently accounting for approximately 60% of its revenue.